CN102453713A - HULC siRNA及其在制备治疗肝癌的药物中的用途 - Google Patents
HULC siRNA及其在制备治疗肝癌的药物中的用途 Download PDFInfo
- Publication number
- CN102453713A CN102453713A CN2010105124125A CN201010512412A CN102453713A CN 102453713 A CN102453713 A CN 102453713A CN 2010105124125 A CN2010105124125 A CN 2010105124125A CN 201010512412 A CN201010512412 A CN 201010512412A CN 102453713 A CN102453713 A CN 102453713A
- Authority
- CN
- China
- Prior art keywords
- hulc
- sirna
- cell
- liver cancer
- expression vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004459 Small interfering RNA Proteins 0.000 title claims abstract description 69
- 201000007270 liver cancer Diseases 0.000 title claims abstract description 44
- 208000014018 liver neoplasm Diseases 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000003814 drug Substances 0.000 title claims abstract description 8
- 229940079593 drug Drugs 0.000 title abstract 3
- 239000013604 expression vector Substances 0.000 claims abstract description 29
- 210000004027 cell Anatomy 0.000 claims description 67
- 230000014509 gene expression Effects 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 7
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- 230000009465 prokaryotic expression Effects 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229940000406 drug candidate Drugs 0.000 abstract 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 30
- 206010028980 Neoplasm Diseases 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 18
- 238000001890 transfection Methods 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000006907 apoptotic process Effects 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 230000009368 gene silencing by RNA Effects 0.000 description 8
- 238000003757 reverse transcription PCR Methods 0.000 description 8
- 108091030071 RNAI Proteins 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 108020004417 Untranslated RNA Proteins 0.000 description 6
- 102000039634 Untranslated RNA Human genes 0.000 description 6
- 108091027963 non-coding RNA Proteins 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 230000012010 growth Effects 0.000 description 5
- 102000042567 non-coding RNA Human genes 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- 201000010989 colorectal carcinoma Diseases 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 108091070501 miRNA Proteins 0.000 description 4
- 239000002679 microRNA Substances 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 206010027457 Metastases to liver Diseases 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 230000006909 anti-apoptosis Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- -1 carbon ester Chemical class 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 108091007412 Piwi-interacting RNA Proteins 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 1
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 1
- 241000405217 Viola <butterfly> Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000004691 chief cell of stomach Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 108091061970 miR-26a stem-loop Proteins 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010512412.5A CN102453713B (zh) | 2010-10-20 | 2010-10-20 | HULC siRNA及其在制备治疗肝癌的药物中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010512412.5A CN102453713B (zh) | 2010-10-20 | 2010-10-20 | HULC siRNA及其在制备治疗肝癌的药物中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102453713A true CN102453713A (zh) | 2012-05-16 |
CN102453713B CN102453713B (zh) | 2014-02-19 |
Family
ID=46037411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010512412.5A Active CN102453713B (zh) | 2010-10-20 | 2010-10-20 | HULC siRNA及其在制备治疗肝癌的药物中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102453713B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9227956B2 (en) | 2013-04-17 | 2016-01-05 | Pfizer Inc. | Substituted amide compounds |
CN106282321A (zh) * | 2015-05-26 | 2017-01-04 | 中山大学 | 由组织snoRNA组成的肝癌复发风险预测标志物及试剂盒 |
CN108236722A (zh) * | 2018-01-16 | 2018-07-03 | 无锡市第三人民医院 | Idnk抑制剂在制备肝癌治疗药物中的用途 |
CN109475729A (zh) * | 2016-07-21 | 2019-03-15 | 昂热大学 | 用于局部注射的可植入医疗装置 |
CN112359110A (zh) * | 2020-10-29 | 2021-02-12 | 温州医科大学 | 一种胆管癌预后测定标志物、检测引物、试剂盒及应用 |
CN113005179A (zh) * | 2021-02-26 | 2021-06-22 | 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) | 一种基于dna-多肽探针技术定量核酸的质谱方法和应用 |
CN115717142A (zh) * | 2022-05-12 | 2023-02-28 | 北京肿瘤医院(北京大学肿瘤医院) | silncRNA16、纳米靶向药物及其治疗铂类耐药肿瘤中的用途 |
-
2010
- 2010-10-20 CN CN201010512412.5A patent/CN102453713B/zh active Active
Non-Patent Citations (3)
Title |
---|
MATOUK IJ: "Highly upregulated in liver cancer noncoding RNA is overexpressed in hepatic colorectal metastasis", 《EUR J GASTROENTEROL HEPATOL》 * |
PANZITT K: "Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA", 《GASTROENTEROLOGY》 * |
WANG J: "CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer", 《NUCLEIC ACIDS RES》 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9227956B2 (en) | 2013-04-17 | 2016-01-05 | Pfizer Inc. | Substituted amide compounds |
CN106282321A (zh) * | 2015-05-26 | 2017-01-04 | 中山大学 | 由组织snoRNA组成的肝癌复发风险预测标志物及试剂盒 |
CN109475729A (zh) * | 2016-07-21 | 2019-03-15 | 昂热大学 | 用于局部注射的可植入医疗装置 |
CN108236722A (zh) * | 2018-01-16 | 2018-07-03 | 无锡市第三人民医院 | Idnk抑制剂在制备肝癌治疗药物中的用途 |
CN112359110A (zh) * | 2020-10-29 | 2021-02-12 | 温州医科大学 | 一种胆管癌预后测定标志物、检测引物、试剂盒及应用 |
CN113005179A (zh) * | 2021-02-26 | 2021-06-22 | 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) | 一种基于dna-多肽探针技术定量核酸的质谱方法和应用 |
CN113005179B (zh) * | 2021-02-26 | 2021-11-16 | 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) | 一种基于dna-多肽探针技术定量核酸的质谱方法和应用 |
CN115717142A (zh) * | 2022-05-12 | 2023-02-28 | 北京肿瘤医院(北京大学肿瘤医院) | silncRNA16、纳米靶向药物及其治疗铂类耐药肿瘤中的用途 |
Also Published As
Publication number | Publication date |
---|---|
CN102453713B (zh) | 2014-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pallante et al. | MicroRNA deregulation in human thyroid papillary carcinomas | |
Feng et al. | miR-126 functions as a tumour suppressor in human gastric cancer | |
CN102453713B (zh) | HULC siRNA及其在制备治疗肝癌的药物中的用途 | |
Qian et al. | MicroRNA expression profile of bronchioalveolar stem cells from mouse lung | |
JP2011511634A (ja) | ガン幹細胞に関連する方法および組成物 | |
Pigazzi et al. | MicroRNA-34b promoter hypermethylation induces CREB overexpression and contributes to myeloid transformation | |
Gandellini et al. | Emerging role of microRNAs in prostate cancer: implications for personalized medicine | |
CN104818334B (zh) | 与肺腺癌转移相关的微小rna | |
CN102892898A (zh) | 用于肝细胞癌诊断的含微rna生物标记的诊断试剂盒和方法 | |
CN110452907A (zh) | 靶向长链非编码rna ddx11-as1的aso、试剂盒及在肝癌治疗中的应用 | |
CN108467891A (zh) | Snhg5在乳腺癌诊断及评估和疗效预测中的应用 | |
CN109593848A (zh) | 一种肿瘤相关序列、长链非编码rna及其应用 | |
CN104208723B (zh) | miR-638在抗急性髓系白血病中的应用 | |
Wu et al. | MicroRNA-345 functions as a tumor suppressor via targeting ZEB2 in oral squamous cell carcinoma | |
Malpeli et al. | MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways | |
KR20110015013A (ko) | 결장직장암의 평가 방법 및 여기에 사용하기 위한 조성물 | |
CN102399870B (zh) | 一种确定食道癌病人生存预后的试剂 | |
CN111378664B (zh) | 一种环状rna及其应用 | |
CN106636444B (zh) | Fam78a基因的用途 | |
CN105603117B (zh) | miR-3613用于区分肺鳞癌转移与非转移的miRNA标志物 | |
JP5546064B2 (ja) | 肺がん予後および薬物調製における2つのマイクロRNAsの使用 | |
CN106729756A (zh) | 生物标志物作为靶标在肺腺癌诊治中的应用 | |
CN106222169A (zh) | 长链非编码rna apoc1p1-3基因及其用途 | |
CN107184983B (zh) | 一种肺腺癌的诊治靶标 | |
CN106754933B (zh) | 一种siRNA及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: TUMOR HOSPITAL, CHINESE MEDICAL ACADEMY Free format text: FORMER OWNER: TUMOUR INST., CHINA MEDICAL SCIENCE RESEARCH ACADEMY Effective date: 20150804 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150804 Address after: 100021 Beijing, Panjiayuan, South Lane, No. 17, No. Patentee after: Tumor Hospital, Chinese Medical Academy Address before: 100021 Beijing, Panjiayuan, South Lane, No. 17, No. Patentee before: Tumour Inst., China Medical Science Research Academy |